SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer
NCT06402435
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Lvonescimab (AK112)
Sponsor
Hubei Cancer Hospital